Home > Health Conditions > Diabetes > Rezulin (troglitazone)

Rezulin (troglitazone) Parke-Davis (removed from US market)

Related Topics:

• Actos (pioglitazone HCl) / Amaryl (glimepiride) / Avandia (rosiglitazone) / Byetta (exenatide) / Diabeta, Micronase (glyburide) / Farxiga (dapagliflozin) / Glucophage (metformin) / insulin / Invokana (canagliflozin) / Januvia (sitagliptin) / Jardiance (empagliflozin) / Lantus (glargine) / Onglyza (saxagliptin) / Prandin™ (repaglinide) / Precose (acarbose) / Rezulin (troglitazone) / Starlix® (nateglinide) / Symlin (pramlintide acetate) / Victoza (liraglutide)

News & Research:

• Insulin-sensitizing Drug Cut Diabetes Risk - Science Daily, 4/12/05 - "troglitazone lowered diabetes onset by 75 percent"
• Troglitazone Improves Endothelial Function And Fasting Plasma Insulin Concentrations - Doctor's Guide, 3/4/03
• Troglitazone Improves Cardiovascular Risk Factors Better Than Metformin In Type 2 Diabetes - Doctor's Guide, 3/11/02
• Troglitazone Augments Fatty Acid Flux Suppression By Insulin - Doctor's Guide, 2/25/02
• Troglitazone Drug Helps non-Diabetic Patients Lose Weight - Doctor's Guide, 6/20/01
• Troglitazone Improves Ovulation And Hirsutism In Women With Polycystic Ovary Syndrome - Doctor's Guide, 4/11/01
• Troglitazone Safe And Effective In Triple Therapy - Doctor's Guide, 6/21/99
• Troglitazone Successful As Combination Therapy For Diabetics - Doctor's Guide, 6/21/99
• FDA, Parke-Davis Urge Limits On Rezulin Use - Doctor's Guide, 6/17/99
• Diabetes Drug Troglitazone Slows Tumour Cells Growth - Doctor's Guide, 3/30/99
• FDA Panel Says Rezulin Should Stay On Market - Doctor's Guide, 3/29/99
• Metformin/Troglitazone Combination Improves Diabetes Control - Doctor's Guide, 3/25/98
• Rezulin Labeling Changes Result Of Potential Liver Injury Risk - Doctor's Guide, 11/6/97
• Rezulin For Type II Diabetes Cleared By FDA - Doctor's Guide, 1/30/97
• NIH Tests Rezulin as Part of Prevention Study - Doctor's Guide, 1/30/97

Abstracts:

• Thiazolidinedione (TZD) Use and Bone Loss in Older Diabetic Adults - J Clin Endocrinol Metab. 2006 Apr 11 - "each year of TZD use was associated with greater bone loss at the whole body (additional loss of -0.61% per year; 95% CI: -1.02, -0.21% per year), lumbar spine (-1.23% per year; 95% CI: -2.06, -0.40% per year), and trochanter (-0.65% per year; 95% CI: -1.18, -0.12% per year) in women, but not men, with diabetes"

Related Sites:

• Doctor's Guide search of Rezulin
• Doctor's Guide (2) search of Rezulin or troglitazone
• Life Extension Foundation search
• Medline search of troglitazone
• Medscape search of Rezulin or troglitazone
• Nutrition Science News search
• RxList search of troglitazone
• WebMD search of troglitazone

70526